Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insmed Incorporated - Common Stock (NQ:INSM)

131.47 +2.02 (+1.56%)
Streaming Delayed Price Updated: 2:33 PM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Insmed Incorporated - Common Stock

< Previous 1 2 3 4 5 6 Next >
$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Lung Disease-Focused Insmed 'Must-Own' Name For Investors
Insmed gains FDA approval for Brinsupri in bronchiectasis, while analysts see multi-billion sales potential from its expanding pipeline through 2035 
Via Benzinga
Intel, UnitedHealth, And Reddit Are Among Top Large Cap Gainers Last Week (August 11-August 15): Are The Others In Your Portfolio?
These 10 large-cap stocks gained this week, some due to positive news such as media rights deals or FDA approvals. 
Via Benzinga
Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease
Via Stocktwits
Earnings Scheduled For August 7, 2025
 
Via Benzinga
What Does the Market Think About Insmed?
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Assessing Insmed: Insights From 20 Financial Analysts
 
Via Benzinga
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy. 
Via Stocktwits
Nvidia To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic
Insmed shares surged after U.S. regulators approved Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis. 
Via Stocktwits
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
The FDA approves Insmed's Brinsupri for NCFB, cutting exacerbations and slowing the decline of lung function in Phase 3 trial patients. 
Via Benzinga
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval
Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a lung condition. 
Via Investor's Business Daily
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?
Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it. 
Via Investor's Business Daily
Cramer Says Tesla Dominates While Ouster Is 'Too Speculative'
Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option for... 
Via Benzinga
Topics Artificial Intelligence
A Glimpse Into The Expert Outlook On Insmed Through 12 Analysts
 
Via Benzinga
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
 
Via Benzinga
Russell Rebalance: 3 Stocks Ready to Move Higher
The Russell reconstitution is underway; here are three stocks that are garnering interest as stocks that could move up to the Russell 1000 
Via MarketBeat
Oracle, AST SpaceMobile And Halliburton Are Among Top 10 Large Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio?
Top 10 large-cap stocks with biggest gains last week: INSM, CRCL, ORCL, ASTS, SAIL, VG, TEM, CASY, EQNR, HAL. Have you invested in them? 
Via Benzinga
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast
BofA raises Insmed price target to $109 after strong TPIP data and flags FDA decision on brensocatib as a near-term share catalyst. 
Via Benzinga
Datadog To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Deep Dive Into Insmed Stock: Analyst Perspectives (6 Ratings)
 
Via Benzinga
Dow Gains 50 Points; US Small Business Optimism Index Rises In May
 
Via Benzinga
Topics Stocks
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Which stocks are gapping on Tuesday?
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Insmed Stock Soars Pre-market After Lung Disease Drug Achieves Positive Results In Mid-Stage Trial: Retail Gets More Bullish
Insmed said that it will immediately engage with the U.S. Food and Drug Administration (FDA) regarding a late-stage study design following the positive results from the mid-stage trial. 
Via Stocktwits
Topics Death
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.